In a report released today, Vamil Divan from Credit Suisse maintained a Buy rating on Allergan (AGN), with a price target of $197. The company’s shares opened today at $143.10.
According to TipRanks.com, Divan has 0 stars on 0-5 star ranking scale with an average return of -3.9% and a 39.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
Currently, the analyst consensus on Allergan is a Moderate Buy with an average price target of $208.31, representing a 45.6% upside. In a report issued on January 3, Merrill Lynch also maintained a Buy rating on the stock with a $204 price target.
.
See today’s analyst top recommended stocks >>
Based on Allergan’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $37.9 million. In comparison, last year the company had a net profit of $3.12 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.
